spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  diabetic peripheral neuropathic 

 HSMN NewsFeed - 24 May 2021
Eliem Therapeutics Announces $60 Million Series B Financing
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 31 Aug 2017
Daiichi Sankyo Announces Positive Top-line Results from Phase 3 Clinical Trial Evaluating Mirogabalin in Diabetic Peripheral Neuropathic Pain
Biopharmaceuticals
 HSMN NewsFeed - 30 Jun 2017
Daiichi Sankyo Announces Top-line Results from Phase 3 Global Clinical Development Program Evaluating Mirogabalin in Pain Syndromes
Biopharmaceuticals
 HSMN NewsFeed - 22 Nov 2010
Impax Laboratories Receives Tentative FDA Approval for Generic Cymbalta(R) Delayed-Release 20, 30 and 60 mg Capsules
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 3 May 2010
AVANIR Pharmaceuticals Announces Hiring of Michael McFadden as Vice President of U.S. Sales and Managed Markets
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 3 Feb 2010
Cymbalta(R) Significantly Reduced Chronic Low Back Pain in New Study
Biopharmaceuticals
 HSMN NewsFeed - 1 Dec 2009
New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Nov 2009
FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Sep 2009
New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta(R)
Biopharmaceuticals
 HSMN NewsFeed - 30 Jan 2009
Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study
Biopharmaceuticals
 HSMN NewsFeed - 10 Dec 2008
Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R)
Biopharmaceuticals
 HSMN NewsFeed - 28 Nov 2008
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
Biopharmaceuticals
 HSMN NewsFeed - 18 Nov 2008
Impax Sued Based on Anda for Generic Cymbalta(R)
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 25 Aug 2008
Patients Taking Cymbalta(R) Experienced Reduced Chronic Low Back Pain in New Study
Biopharmaceuticals
 HSMN NewsFeed - 22 Aug 2008
Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Jun 2008
European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 16 Jun 2008
FDA Approves Cymbalta(R) for the Management of Fibromyalgia
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Jun 2008
Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
Biopharmaceuticals
 HSMN NewsFeed - 29 May 2008
Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Biopharmaceuticals
 HSMN NewsFeed - 18 Jan 2008
In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
Biopharmaceuticals
 HSMN NewsFeed - 30 Nov 2007
FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Oct 2007
AVANIR Granted Special Protocol Assessment (SPA) From FDA for Confirmatory Phase III Trial of Zenvia in Patients With PBA
Biopharmaceuticals Neurology
 HSMN NewsFeed - 21 Aug 2007
New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
Biopharmaceuticals
 HSMN NewsFeed - 6 Aug 2007
AVANIR Pharmaceuticals Completes Sale Of FazaClo
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 3 Jul 2007
AVANIR Pharmaceuticals Announces Sale of FazaClo to Fund Continued Development of Zenvia
Biopharmaceuticals
 HSMN NewsFeed - 8 Jun 2007
AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at International Congress on Neuropathic Pain
Biopharmaceuticals
 HSMN NewsFeed - 31 May 2007
AVANIR Receives FDA Approval for New Formulation of Currently Marketed Antipsychotic Drug FazaClo
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 May 2007
Data Suggest Cymbalta(R) Improved Functioning in Patients With Generalized Anxiety Disorder
Biopharmaceuticals
 HSMN NewsFeed - 3 May 2007
Data Suggest Cymbalta(R) Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Biopharmaceuticals
 HSMN NewsFeed - 26 Feb 2007
FDA Approves Cymbalta(R) for Treatment of Generalized Anxiety Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 May 2006
New Data Presented on the Effect of Cymbalta(R) on Sexual Function in Depressed Patients
Biopharmaceuticals
 HSMN NewsFeed - 9 May 2006
Lilly Submits Cymbalta(R) Supplemental New Drug Application for Generalized Anxiety Disorder
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 12

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 12 additional stories matching:
diabetic peripheral neuropathic
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.